RNA, Messenger - Metabolism
Research News and Information

Saturday, November 21, 2009

Cell cycle-related kinase supports ovarian carcinoma cell proliferation via regulation of cyclin D1 and is a predictor of outcome in patients with ovarian carcinoma.

29 Nov 2009 Our previous study has suggested that the cell cycle-related kinase (CCRK) is a putative candidate oncogene in glioblastoma tumorigenesis. The potential oncogenic role of CCRK and its clinical/prognostic significance, however, in ovarian carcinoma ... Read more...

Prostaglandin E(2) promotes cell proliferation via protein kinase C/extracellular signal regulated kinase pathway-dependent induction of c-Myc expression in human esophageal squamous cell carcinoma cells.

29 Nov 2009 Overexpression of cyclooxygenase-2 (COX-2) and elevation of its derivative prostaglandin E(2) (PGE(2)) are implicated in human esophageal squamous cell carcinoma. The expression of c-Myc, an oncogenic transcription factor, is also upregulated in ... Read more...

Downregulation of p21-activated kinase-1 inhibits the growth of gastric cancer cells involving cyclin B1.

29 Nov 2009 p21-Activated kinase 1 (Pak1), a serine/threonine kinase, has been implicated in cytoskeletal remodelling, cell motility, apoptosis and transformation. However, the role of Pak1 in gastric cancer remains unclear. In this study, we detected Pak1 ... Read more...

Latest indexed articles for 'RNA, Messenger - Metabolism'

These are the very latest articles for this heading:

• Cell cycle-related kinase supports ovarian carcinoma cell proliferation via regulation of cyclin D1 and is a predictor of outcome in patients with ovarian carcinoma. 29 Nov 2009
• Prostaglandin E(2) promotes cell proliferation via protein kinase C/extracellular signal regulated kinase pathway-dependent induction of c-Myc expression in human esophageal squamous cell carcinoma cells. 29 Nov 2009
• Downregulation of p21-activated kinase-1 inhibits the growth of gastric cancer cells involving cyclin B1. 29 Nov 2009
• Differential oncogenic potential of geographically distinct Helicobacter pylori CagA isoforms in mice. 29 Nov 2009
• Overexpression of low-density lipoprotein receptor and lipid accumulation in intestinal polyps in Min mice. 29 Nov 2009
• HER3 is required for the maintenance of neuregulin-dependent and -independent attributes of malignant progression in prostate cancer cells. 29 Nov 2009
• Elevated levels of MIC-1/GDF15 in the cerebrospinal fluid of patients are associated with glioblastoma and worse outcome. 29 Nov 2009
• Sphingosine kinase 1 inhibition sensitizes hormone-resistant prostate cancer to docetaxel. 29 Nov 2009
• Expression and role of CXCL10 during the encephalitic stage of experimental and clinical African trypanosomiasis. 13 Nov 2009
• The reduction of cell death and proliferation by p27(Kip1) minimizes DNA damage in an experimental model of genotoxicity. 13 Nov 2009
• Serum olfactomedin 4 (GW112, hGC-1) in combination with Reg IV is a highly sensitive biomarker for gastric cancer patients. 13 Nov 2009
• Chromosomal abnormalities and novel disease-related regions in progression from Barrett's esophagus to esophageal adenocarcinoma. 13 Nov 2009
• Blockade of TRPC6 channels induced G2/M phase arrest and suppressed growth in human gastric cancer cells. 13 Nov 2009
• Distinct progression-associated expression of tumor and stromal MMPs in HaCaT skin SCCs correlates with onset of invasion. 13 Nov 2009
• Clinical and biological significance of CXCR5 expressed by prostate cancer specimens and cell lines. 13 Nov 2009
• Expression and role of adrenomedullin in renal tumors and value of its mRNA levels as prognostic factor in clear-cell renal carcinoma. 13 Nov 2009
• Enhanced expression of Annexin A4 in clear cell carcinoma of the ovary and its association with chemoresistance to carboplatin. 13 Nov 2009
• CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells. 13 Nov 2009
• Translational regulation by the 3' untranslated region of the dengue type 2 virus genome. 30 Oct 2009
• Tenascin-X is a novel diagnostic marker of malignant mesothelioma. 30 Oct 2009

See a longer list of these articles.

Technical information about 'RNA, Messenger'

Definition: RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.

Registry Number: 0

Descriptor UI: D012333

Alternative terms: RNA, Messenger; mRNA; Messenger RNA; RNA, Polyadenylated; Polyadenylated RNA; Poly(A)+ RNA; Poly(A) RNA; Poly(A) Tail; mRNA, Non-Polyadenylated; mRNA, Non Polyadenylated; Non-Polyadenylated mRNA; Non Polyadenylated mRNA; mRNA, Polyadenylated; RNA, Messenger, Polyadenylated; Polyadenylated mRNA; Messenger RNA, Polyadenylated; Polyadenylated Messenger RNA; RNA, Polyadenylated Messenger; Poly(A)+ mRNA;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; biosynthesis; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; drug effects; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; physiology; poisoning; radiation effects; secretion; standards; supply & distribution; therapeutic use; toxicity; ultrastructure; urine; chemistry; contraindications; agonists;

Tree Number: D13.444.735.544;

Online Note: use RNA, MESSENGER (NM) to search MRNA, NON-POLYADENYLATED 1981-94, MRNA, POLYADENYLATED 1980-94, & POLY(A)+ RNA 1980-94

History Note: 65(64); MRNA, NON-POLYADENYLATED was NON-POLYADENYLATED MRNA (NM) 1981-94; MRNA, POLYADENYLATED was POLYADENYLATED MRNA (NM) 1980-94; POLY(A)+ RNA was SY to POLY(A) RNA (NM) 1980-94

Technical Notes: IM; /drug eff /ultrastruct permitted; DF: note short X ref